Home Journals Articles Updates About
CN
image
收藏切换
Pharmacoeconomics of trilaciclib in the prevention of chemotherapy-induced myelosuppression
收藏切换
PDF
Wei-cheng LEI1, Chen-chen GUO2, Bao-ping DU1, Tao LIU1, Wei-ting LIANG1
Chinese Journal of New Drugs | 2023, 32(23) : 2354 - 2359
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(23): 2354-2359
Pharmacoeconomics of trilaciclib in the prevention of chemotherapy-induced myelosuppression
Full
Wei-cheng LEI1, Chen-chen GUO2, Bao-ping DU1, Tao LIU1, Wei-ting LIANG1
Affiliations
  • 1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
  • 2School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
Published: 2023-12-15
Outline
收藏切换

Chemotherapy still plays pivotal roles in the comprehensive treatment of tumors. Chemotherapy-induced myelosuppression (CIM) is the most common adverse event of chemotherapy, which has posed serious impacts on the anti-tumor efficacy of chemotherapy and the quality of patients' lives, and also resulted in increased treatment burden of patients and more medical resources at the same time. Trilaciclib is a highly potent, selective, reversible cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Clinical data showed that trilaciclib could temporarily arrest bone marrow cells in G1 phase to reduce the incidences of CIM and the proportion of chemotherapy dose adjustment and delay, increasing the tolerance of chemotherapy and reducing the economic burden. This article systematically elaborates on the CIM-caused hazards, clinical prevention, and current status of treatment of CIM, as well as the roles of trilaciclib in the prevention of CIM and its economic value, aiming to provide scientific reference for patients to select reasonable prevention and therapeutic treatment regimens of CIM.

chemotherapy  /  myelosuppression  /  trilaciclib  /  pharmacoeconomics
Wei-cheng LEI, Chen-chen GUO, Bao-ping DU, Tao LIU, Wei-ting LIANG. Pharmacoeconomics of trilaciclib in the prevention of chemotherapy-induced myelosuppression[J]. Chinese Journal of New Drugs, 2023 , 32 (23) : 2354 -2359 .
Appendix
Less
Year 2023 volume 32 Issue 23
PDF
35
13
Cite this Article
BibTeX
Article Info
  • Online Date：2026-03-05
  • Published：2023-12-15
Article Data
Affiliations
History
  • Accepted：2023-10-09
Affiliations
    1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
    2School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House